• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Mid-Day Market Update: Nasdaq Surges 150 Points; US Crude Oil Inventories Fall By 2.6M Barrels

    3/2/22 12:10:38 PM ET
    $AKA
    $ARLO
    $JWN
    $KPTI
    Catalog/Specialty Distribution
    Consumer Discretionary
    Consumer Electronics/Appliances
    Consumer Staples
    Get the next $AKA alert in real time by email

    U.S. stocks extended gains midway through trading, with the Nasdaq index jumping 150 points on Wednesday.

    The Dow traded up 1.71% to 33,865.43 while the NASDAQ rose 1.11% to 13,682.58. The S&P also rose, gaining, 1.56% to 4,377.68.

    Check out this: Insiders Buy Around $98M Of 3 Stocks

    Leading and Lagging Sectors


    Financials shares climbed by 2.7% on Wednesday. Meanwhile, top gainers in the sector included Prudential Bancorp, Inc. (NASDAQ:PBIP), up 18% and Qudian Inc. (NYSE:QD) up 10%.


    In trading on Wednesday, communication services shares rose by just 0.6%.


    Top Headline


    US crude oil inventories dropped by 2.597 million barrels in the week ended February 25th, versus a 4.515 million increase in the prior period, the Energy Information Administration said. However, analysts were expecting for a 2.748 million barrel gain.


    Equities Trading UP


    Nordstrom, Inc. (NYSE:JWN) shares shot up 39% to $27.11 after the company reported better-than-expected Q4 EPS and sales results. The company also issued FY22 guidance.


    Shares of Arlo Technologies, Inc. (NYSE:ARLO) got a boost, shooting 31% to $11.34 after the company reported better-than-expected Q4 results. The company also issued Q1 sales guidance above analyst estimates.


    Organogenesis Holdings Inc. (NASDAQ:ORGO) shares were also up, gaining 22% to $8.86 after the company reported Q4 EPS results up from last year and better-than-expected sales results.

    Also check this: Cisco Systems And 3 Other Stocks Sold By Insiders


    Equities Trading DOWN

    SAB Biotherapeutics, Inc. (NASDAQ:SABS) shares tumbled 39% to $2.81. SAB Biotherapeutics said that due to low hospitalization and death rates in the trial, the National Institutes of Health's (NIH) ACTIV-2 Program is discontinuing enrollment in its Phase 3 COVID-19 trial.


    Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) were down 34% to $6.88 after the company announced it received feedback from the FDA that the current SIENDO study top-line results are unlikely to support an sNDA approval.


    a.k.a. Brands Holding Corp. (NYSE:AKA) was down, falling 22% to $5.43 after the company issued Q1 sales guidance below analyst estimates.

    Also check out: Executives Buy Around $1M Of 5 Penny Stocks


    Commodities

    In commodity news, oil traded up 5.7% to $109.28, while gold traded down 0.6% to $1,931.50.


    Silver traded down 1.3% Wednesday to $25.21 while copper rose 1.5% to $4.6695.



    Euro zone

    European shares were higher today. The eurozone’s STOXX 600 gained 0.90%, London’s FTSE 100 rose 1.36%, while Spain’s IBEX 35 Index rose 1.62%. The German DAX gained 0.69%, French CAC 40 climbed 1.59% and Italy’s FTSE MIB Index gained 0.70%.

    Annual inflation rate in the Eurozone increased to a fresh record high of 5.8% in February from 5.1% in January. The unemployment rate in Germany fell to 5% in February from 5.1% in January. The number of people registered as unemployed in Spain declined by 11,394 from a month ago to 3.11 million during February.

    French government budget deficit narrowed to EUR 15.9 billion in January from EUR 21.9 billion in the previous month. House prices in the UK surged by 12.6% year-over-year in February.


    Economics


    Private businesses hired 475,000 workers in February, the ADP said.


    US crude oil inventories dropped by 2.597 million barrels in the week ended February 25th, versus a 4.515 million increase in the prior period, the Energy Information Administration said. However, analysts were expecting for a 2.748 million barrel gain.


    The Federal Open Market Committee will release its Beige Book report at 2:00 p.m. ET.


    Check out this: 4 Penny Stocks Insiders Are Buying

    Check out the full economic calendar here

    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 80,697,920 cases with around 977,400 deaths. India confirmed a total of at least 42,938,590 cases and 514,240 deaths, while Brazil reported over 28,811,160 COVID-19 cases with 649,710 deaths. In total, there were at least 439,261,310 cases of COVID-19 worldwide with more than 5,986,710 deaths.

    Get the next $AKA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKA
    $ARLO
    $JWN
    $KPTI

    CompanyDatePrice TargetRatingAnalyst
    Karyopharm Therapeutics Inc.
    $KPTI
    3/10/2026$28.00Buy
    Rodman & Renshaw
    Karyopharm Therapeutics Inc.
    $KPTI
    2/5/2026Overweight
    Cantor Fitzgerald
    SAB Biotherapeutics Inc.
    $SABS
    12/19/2025$15.00Buy
    Guggenheim
    Karyopharm Therapeutics Inc.
    $KPTI
    10/13/2025$15.00Neutral → Buy
    H.C. Wainwright
    SAB Biotherapeutics Inc.
    $SABS
    9/17/2025$7.00Outperform
    Leerink Partners
    Arlo Technologies Inc.
    $ARLO
    8/8/2025$17.00 → $22.00Buy
    Craig Hallum
    a.k.a. Brands Holding Corp.
    $AKA
    8/7/2025$10.00 → $13.00Market Perform
    Telsey Advisory Group
    Karyopharm Therapeutics Inc.
    $KPTI
    7/16/2025Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $AKA
    $ARLO
    $JWN
    $KPTI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Leibowitz Arthur S bought $13,405 worth of shares (5,000 units at $2.68), increasing direct ownership by 2% to 291,014 units (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    3/11/26 9:45:54 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Driscoll Michael Joseph bought $26,688 worth of shares (10,000 units at $2.67), increasing direct ownership by 5% to 225,707 units (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    3/11/26 5:45:41 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Nussdorf Glenn H bought $1,096,039 worth of shares (358,495 units at $3.06) and sold $80,803 worth of shares (22,776 units at $3.55) (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    11/3/25 5:25:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKA
    $ARLO
    $JWN
    $KPTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on Karyopharm Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of Karyopharm Therapeutics with a rating of Buy and set a new price target of $28.00

    3/10/26 8:41:07 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Karyopharm Therapeutics

    Cantor Fitzgerald initiated coverage of Karyopharm Therapeutics with a rating of Overweight

    2/5/26 6:58:02 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on SAB BIO with a new price target

    Guggenheim initiated coverage of SAB BIO with a rating of Buy and set a new price target of $15.00

    12/19/25 8:51:08 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AKA
    $ARLO
    $JWN
    $KPTI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Petal & Pup Celebrates Australian Roots and Global Growth with New Brand Identity

    New brand campaign marks the evolution of the women-led brand and its connection to women everywhere. SAN FRANCISCO, March 13, 2026 /PRNewswire/ -- a.k.a. Brands Holding Corp. (NYSE:AKA), a portfolio of next generation fashion brands, today announces the launch of Petal & Pup's global evergreen brand campaign and the official debut of the brand's evolved identity. Rooted in Petal & Pup's carefree Australian spirit, the evergreen campaign invites women everywhere to see themselves reflected in a shared joy for dressing up, connection, and the beauty found in life's moments, big a

    3/13/26 9:00:00 AM ET
    $AKA
    Catalog/Specialty Distribution
    Consumer Discretionary

    SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes

    Results demonstrated early signals of C-peptide preservation T1D key opinion leader, Michael J. Haller, MD, provided a recorded webinar reviewing the SAB-142 Phase 1 data MIAMI, March 10, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced additional data from the Phase 1 HUman anti-thymocyte biologic in first-in-MAN (HUMAN) clinical trial of SAB-142. The established T1D adult patient cohort demonstrated early signals of C-peptide preservation which aligned with the anticipated mechanism of action o

    3/10/26 7:31:00 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SAB BIO Reports Full Year 2025 Financial Results and Business Highlights

    Advanced SAB -142 into registrational Phase 2b SAFEGUARD study with multiple patients dosed; enrollment ongoing and on track to complete enrollment by end of 2026 with topline data expected in 2H 2027 Reported Phase 1 clinical data, including healthy volunteer, redosing, and T1D cohorts supporting SAB-142's favorable safety profile, redosability, and continued clinical development Raised $175 million in an oversubscribed private placement with leading institutional and strategic investors to fully fund SAFEGUARD Strong cash position with operational runway through 2028 MIAMI, March 09, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutica

    3/9/26 5:16:37 PM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AKA
    $ARLO
    $JWN
    $KPTI
    SEC Filings

    View All

    SEC Form 144 filed by Arlo Technologies Inc.

    144 - Arlo Technologies, Inc. (0001736946) (Subject)

    3/12/26 7:27:58 PM ET
    $ARLO
    Consumer Electronics/Appliances
    Consumer Staples

    SEC Form 144 filed by Arlo Technologies Inc.

    144 - Arlo Technologies, Inc. (0001736946) (Subject)

    3/12/26 7:27:47 PM ET
    $ARLO
    Consumer Electronics/Appliances
    Consumer Staples

    SAB Biotherapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - SAB Biotherapeutics, Inc. (0001833214) (Filer)

    3/10/26 7:35:30 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AKA
    $ARLO
    $JWN
    $KPTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    GENERAL COUNSEL Busse Brian sold $351,609 worth of shares (25,525 units at $13.78) and converted options into 50,000 shares, increasing direct ownership by 4% to 583,364 units (SEC Form 4)

    4 - Arlo Technologies, Inc. (0001736946) (Issuer)

    3/12/26 7:42:04 PM ET
    $ARLO
    Consumer Electronics/Appliances
    Consumer Staples

    CHIEF FINANCIAL OFFICER Binder Kurtis Joseph converted options into 333,334 shares and sold $2,471,533 worth of shares (179,419 units at $13.78), increasing direct ownership by 33% to 614,885 units (SEC Form 4)

    4 - Arlo Technologies, Inc. (0001736946) (Issuer)

    3/12/26 7:40:58 PM ET
    $ARLO
    Consumer Electronics/Appliances
    Consumer Staples

    CEO Mcrae Matthew Blake converted options into 288,824 shares and sold $2,113,570 worth of shares (153,433 units at $13.78), increasing direct ownership by 13% to 1,168,866 units (SEC Form 4)

    4 - Arlo Technologies, Inc. (0001736946) (Issuer)

    3/12/26 7:39:41 PM ET
    $ARLO
    Consumer Electronics/Appliances
    Consumer Staples

    $AKA
    $ARLO
    $JWN
    $KPTI
    Financials

    Live finance-specific insights

    View All

    a.k.a. Brands Holding Corp. Reports Fourth Quarter and Full Year 2025 Financial Results

    Delivers Another Consecutive Year of Net Sales Growth; Expands Gross Margin and Enters 2026 with Strengthening Momentum Princess Polly Announces Eight New U.S. Store Leases a.k.a. Brands Holding Corp. (NYSE:AKA), a portfolio of next generation fashion brands, today announced financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter Financial Highlights Net sales increased 3.1% to $164.0 million, compared to $159.0 million in the fourth quarter of 2024; up 2.8% on a constant currency basis1. In the U.S., net sales increased 5.3% compared to the fourth quarter of 2024. Net loss was $(14.5) million, or $(1.35) per share, in the fourth quarter

    3/5/26 4:05:00 PM ET
    $AKA
    Catalog/Specialty Distribution
    Consumer Discretionary

    Arlo Reports Fourth Quarter and Full Year 2025 Results

    Annual recurring revenue (ARR)(1) ended at $330 million, growing 28% year over year Full year subscriptions and services revenue of $316 million, growing 30% year over year Full year GAAP gross margin of 44%, growing 730 basis points and non-GAAP gross margin(2) of 45%, growing 750 basis points Full year adjusted EBITDA(2) of $75 million; adjusted EBITDA margin of 14% Arlo Technologies, Inc. (NYSE:ARLO), a leading smart home security platform company, today reported financial results for the fourth quarter and full year ended December 31, 2025. "Arlo's subscription services strategy delivered blockbuster results in 2025 generating record levels of subscription revenue and profitab

    2/26/26 4:05:00 PM ET
    $ARLO
    Consumer Electronics/Appliances
    Consumer Staples

    Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue

    CANTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2025. Fourth Quarter 2025 Financial Results Summary: Net product revenue of $225.1 million for the fourth quarter of 2025, an increase of $98.4 million compared to net product revenue of $126.7 million for the fourth quarter of 2024. Net product revenue for the fourth quarter of 2025 consis

    2/26/26 4:05:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKA
    $ARLO
    $JWN
    $KPTI
    Leadership Updates

    Live Leadership Updates

    View All

    Arlo Technologies Announces Inducement Awards Under NYSE Rule 303A.08

    SAN JOSE, Calif., Feb. 4, 2026 /PRNewswire/ -- Arlo Technologies, Inc. (NYSE:ARLO), a leading smart home security brand, today announced that it had made equity grants to new employees under its 2018 Equity Incentive Plan in accordance with NYSE Rule 303A.08. On February 4, 2026, Arlo's Compensation and Human Capital Committee granted restricted stock units, or RSUs, to three new non-executive employees covering an aggregate of 17,380 shares of the Company's common stock as an inducement for such employees to join the Company. The RSUs vest annually in four equal annual instal

    2/4/26 6:19:00 PM ET
    $ARLO
    Consumer Electronics/Appliances
    Consumer Staples

    SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director

    David Zaccardelli, Pharm.D. joins Board as Chair Rita Jain, M.D., joins Board as an Independent Director MIAMI, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the appointment of David Zaccardelli, Pharm.D. to its Board of Directors as Chair of the Board and the appointment of Rita Jain, M.D., as an independent director, both effective immediately. "We are excited to welcome Dr. David Zaccardelli and Dr. Rita Jain to our Board of Directors. I, along with the rest of our Board, am confi

    1/7/26 8:00:00 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Arlo Technologies Announces Inducement Awards Under NYSE Rule 303A.08

    SAN JOSE, Calif., Oct. 28, 2025 /PRNewswire/ -- Arlo Technologies, Inc. (NYSE:ARLO), a leading smart home security brand, today announced that it had made equity grants to new employees under its 2018 Equity Incentive Plan in accordance with NYSE Rule 303A.08. On October 28, 2025, Arlo's Compensation and Human Capital Committee granted restricted stock units, or RSUs, to seven new non-executive employees covering an aggregate of 150,255 shares of the Company's common stock as an inducement for such employees to join the Company. The RSU's granted to six of the employees, cover

    10/28/25 3:40:00 PM ET
    $ARLO
    Consumer Electronics/Appliances
    Consumer Staples

    $AKA
    $ARLO
    $JWN
    $KPTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Organogenesis Holdings Inc.

    SC 13D - Organogenesis Holdings Inc. (0001661181) (Subject)

    11/19/24 4:05:57 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Organogenesis Holdings Inc.

    SC 13D/A - Organogenesis Holdings Inc. (0001661181) (Subject)

    11/14/24 8:09:56 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Karyopharm Therapeutics Inc.

    SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)

    11/14/24 4:22:08 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care